Regeneron rises 2.2% after OPTIMA trial adds efficacy data for newly approved drug

What happened

Regeneron (REGN) rose 2.2% on October 12, 2026, after it disclosed 84-week Phase 3 OPTIMA results showing sustained efficacy for its newly approved drug Pasatru. The stock closed at $762.81 after opening 0.3% above the previous close, and trading volume was 0.8 times its 20-day average. Benzinga reported the OPTIMA results, which the company said demonstrated continued control of pathological bone growth for Pasatru through 84 weeks.

How big was the move

The stock’s rise amounted to 1.1 times a typical daily move for this stock, an ordinary session rather than an outsized market reaction. Over the last five sessions the stock rose 5.0% while the S&P 500 rose 0.4% in that span. On the day, the S&P 500 fell 0.1% and the healthcare sector median fell 1.0%, leaving the stock’s performance 3.2 percentage points better than the sector median.

Regeneron’s market sensitivity remains modest, with a beta of 0.59, meaning the stock tends to move less than the broader market. That context helps explain why a materially positive data readout coincided with only a normal-sized market move.

The technical picture

Technically, the stock sat 0.3% below its 20-day moving average and 3.4% below its 50-day moving average, while it remained 3.7% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent five consecutive trading days above its 200-day average. The 14-day Relative Strength Index was 49, squarely in a neutral range between 30 and 70.

Longer-term price action was mixed. The stock was 11.2% below its 52-week high, had fallen 2.4% over one month, yet rose 16.3% over three months and 33.8% over one year. Its one-year performance was 17.9 percentage points ahead of the S&P 500. Volatility measured 30% annualized over 60 days, a level higher than 66% of its own readings over five years, indicating relatively elevated short-term swings compared with its historical pattern.

Fundamentals and valuation

For the four quarters through June 30, 2026, Regeneron reported revenue of $15.53 billion, up 9.3% from a year earlier. Diluted earnings per share for that period were $40.43, an increase of 1.9% from the prior year, and gross margin was 84.9% versus 85.6% a year earlier. Operating margin stood at 25.6% compared with 27.0% a year earlier, and the company reported a free-cash-flow margin of 22.7%.

The balance sheet showed net cash of $469.2 million and the share count decreased by 1.7% over one year. Return on invested capital was 9.2%, a measure of how efficiently the company converts capital into profit. On valuation, the stock traded at 18.9 times trailing earnings, a level higher than 62% of its own readings over the past five years where the five-year median was 18.3 times earnings. Price to forward earnings was 13.3 times expected earnings and free-cash-flow yield was 4.6%.

Taken together, the financials show solid cash generation and high gross margins typical of successful biotechnology firms, while near-term margins have slipped slightly from the prior year. The valuation sits a touch above its five-year median, reflecting both the company’s cash flow profile and recent clinical progress.

Earnings and analyst expectations

Regeneron’s next earnings report is scheduled for October 30, 2026. The company’s last report, on July 30, 2026, delivered earnings per share of $14.29 against $10.16 expected, a surprise of 40.6% above estimates. That marked five consecutive quarters of beating estimates, with an average surprise of 19.0% above estimates across the last four reports. Typical two-day reactions after recent reports have been modest, with the stock rising 0.2% on average.

Analysts provide a consensus price target of $849.84 from 49 analysts, which is 11.4% above the closing price on October 12, 2026. Sixty-nine percent of covering analysts rate the stock Buy, and the consensus rating is Buy. PromtFinance scores rank the company highly on quality and stability, with Value and Momentum also positive relative to peers.

What to watch

• October 30, 2026: next quarterly earnings report.
• Post-approval commercial uptake for Pasatru and additional OPTIMA follow-up data releases.
• Any company updates to revenue or guidance tied to Pasatru commercialization.
• Changes in analyst revisions and the consensus price target among the 49 covering analysts.
• Movement relative to the 50-day and 200-day averages and whether the stock sustains more days above the 200-day average.